MHRA approves capivasertib for treatment of advanced breast cancer

July 25, 2024 Health Trends, Health Trends - UK

The Medicines and Healthcare products Agency (MHRA) has authorised the use of a new drug for the treatment of locally advanced or metastatic HR-positive, HER 2-negative breast cancer.

Capivasertib (Truqap; AstraZeneca), an AKT inhibitor, works by blocking the effects of proteins called AKT…

Source link

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.

MHRA approves capivasertib for treatment of advanced breast cancer

Recent Posts

Recent Comments